The combination of HER2/neu CAR-T cells and oncolytic adenovirus-expressing anti-PD-L1 and IL-2 remarkably improved survival compared with monotherapy in head and neck squamous cell carcinoma xenograft mice [47]. Here, ERBB2 is linked to head and neck squamous cell carcinoma.